ArticleOncology letters2026
Association between the expression of GSTP1 and mutant p53, poor chemotherapy response and metastasis in patients with osteosarcoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma, a primary malignant tumor of the bone, is known for its aggressive behavior and tendency to metastasize to the lungs. The standard treatment for osteosarcoma includes surgery combined with chemotherapy. However, genetic changes and chromosomal contributions influence the tumor's aggressive behavior and influence the effectiveness of chemotherapy, often resulting in drug resistance and metastasis. The present study aimed to assess the association between increased expression of mutant p53 and glutathione S-transferase P1 (GSTP1), poor chemotherapy response and the occurrence of metastasis in patients with osteosarcoma. The study is a cross-sectional study using paraffin blocks retrieved from the Department of Anatomical Pathology at Cipto Mangunkusumo Hospital (Jakarta, Indonesia) containing tissues gathered from patients diagnosed with osteosarcoma who received the first-line drug of neoadjuvant chemotherapy for three cycles from January 2019 to December 2021. Immunohistochemical examinations of GSTP1 and mutant p53 were conducted, using the Fedchenko and Reifenrath immunoreactive scoring system. The results obtained after the immunohistochemical examination and evaluation of GSTP1 expression and mutant p53 expression were subjected to bivariate association analysis with chemotherapy response (Huvos Score) and the occurrence of metastasis. This study involved a total of 36 patients. Statistical analysis using the Fisher's exact test revealed a significant association between increased GSTP1 expression and a poor chemotherapy response, as well as between increased mutant P53 expression and a poor chemotherapy response. By contrast, no significant association was found between GSTP1 or mutant P53 expression and the occurrence of metastasis. In conclusion, a significant association was found between the increasing expression levels of GSTP1 and mutant p53 and a poor chemotherapy response in patients with osteosarcoma, while no significant association was found between the increasing expression of GSTP1 and mutant p53 and the occurrence of metastasis in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.